68Gallium-FAPI PET/CT Imaging in Chronic Inflammatory and Fibrotic Diseases
This single-center pilot study is designed to explore the preliminary utility of the [68Ga] Ga-FAPI imaging agent in positron emission tomography (PET) combined with computed tomography (CT) for a range of chronic inflammatory and fibrosing diseases. The study focuses on the potential of [68Ga] Ga-FAPI, a novel radiotracer targeting Fibroblast Activation Protein (FAP), to improve diagnostic accuracy in various medical conditions. Thirteen distinct clinical situations have been selected for this investigation, including rheumatoid arthritis, liver fibrosis, and systemic lupus, among others. This approach aims to ascertain the value of further clinical development in each area and refine the use of this imaging modality in routine care for both initial evaluation and ongoing monitoring of these diseases.
- EligibilityCriteria: Inclusion Criteria:  Patient aged 18 or over Affected by one of the pathologies concerned by the study Satisfying the consensus classification criteria of the pathology, detailed in the protocol Satisfying the corresponding clinical situation, detailed in the protocol  Exclusion Criteria:  Pregnant or breastfeeding woman Patients unable to consent Patients refusing to participate in research Known active cancer - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult